Aaron K. Sato, Ph.D.
Chief Scientific Officer, Biopharma
Twist Bioscience
Synthetic DNA Technologies Enable Fast and Responsive SARS-CoV-2 Antibody Discovery and Optimization
Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.
Twist Biopharma, a Division of Twist Bioscience
By leveraging our unique ability to manufacture DNA at scale, we can construct proprietary antibody libraries precisely designed to match sequences that occur in the human body. This library of libraries gives our partners an integral and unbiased resource for antibody therapeutic discovery and optimization. This precise and rational approach to library fabrication combined with sophisticated bioinformatics and software expertise expedites antibody discovery by decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.
